Environmental Science and Pollution Research,
Journal Year:
2023,
Volume and Issue:
30(57), P. 120366 - 120374
Published: Nov. 8, 2023
Phthalate
exposure
is
widespread
and
has
a
global
impact.
Growing
evidence
shows
that
mono-2-ethylhexyl
phthalate
(MEHP)
negative
impact
on
human
health.
However,
whether
MEHP
associated
with
mortality
other
adverse
outcomes
in
hemodialysis
patients
remains
unknown.
This
study
prospectively
enrolled
217
maintenance
from
June
30,
2021,
to
August
16,
2022.
Baseline
serum
MEHP,
di-2-ethylhexyl
(DEHP),
indoxyl
sulfate
(IS)
concentrations
were
measured.
Primary
endpoints
all-cause
or
composite
outcomes,
including
death
plus
hospitalization
due
cardiovascular
disease,
heart
failure,
stroke,
infection,
cancer.
Serum
positively
DEHP
but
not
patients.
Additionally,
significantly
independently
(adjusted
hazard
ratios
[HRs],
1.04
1.03
per
ng/mL,
95%
confidence
intervals
[CIs],
1.01-1.07
1.00-1.05;
p
=
0.016
0.015,
respectively).
We
found
cutoff
value
of
for
predicting
both
endpoints.
Patients
≥
41.8
ng/mL
had
much
higher
risks
HRs,
39.2
13;
CIs,
2.44-65.7
2.74-61.4;
0.011
0.001,
outcomes.
Hemodialysis
above
poorer
prognoses
regarding
International Journal of Toxicology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 10, 2024
Endocrine-disrupting
chemicals
(EDCs)
play
an
important
role
in
the
incidence
of
type-2
diabetes.
Di-2-ethyl
hexyl
Phthalate
(DEHP)
is
one
endocrine-disrupting
used
as
a
plasticizer
to
impart
flexibility
and
softness
plastic-containing
materials.
Mono-2-ethylhexyl
(MEHP),
DEHP's
primary
metabolite,
preferentially
absorbed
once
metabolized.
A
previous
study
from
our
laboratory
showed
that
DEHP
MEHP
altered
key
proteins
such
insulin
receptor
(INSR)
glucose
transporter-4
(GLUT4)
L6
myotubes.
In
sequel
study,
present
hypothesized
its
metabolite
may
alter
Environmental Science and Pollution Research,
Journal Year:
2023,
Volume and Issue:
30(57), P. 120366 - 120374
Published: Nov. 8, 2023
Phthalate
exposure
is
widespread
and
has
a
global
impact.
Growing
evidence
shows
that
mono-2-ethylhexyl
phthalate
(MEHP)
negative
impact
on
human
health.
However,
whether
MEHP
associated
with
mortality
other
adverse
outcomes
in
hemodialysis
patients
remains
unknown.
This
study
prospectively
enrolled
217
maintenance
from
June
30,
2021,
to
August
16,
2022.
Baseline
serum
MEHP,
di-2-ethylhexyl
(DEHP),
indoxyl
sulfate
(IS)
concentrations
were
measured.
Primary
endpoints
all-cause
or
composite
outcomes,
including
death
plus
hospitalization
due
cardiovascular
disease,
heart
failure,
stroke,
infection,
cancer.
Serum
positively
DEHP
but
not
patients.
Additionally,
significantly
independently
(adjusted
hazard
ratios
[HRs],
1.04
1.03
per
ng/mL,
95%
confidence
intervals
[CIs],
1.01-1.07
1.00-1.05;
p
=
0.016
0.015,
respectively).
We
found
cutoff
value
of
for
predicting
both
endpoints.
Patients
≥
41.8
ng/mL
had
much
higher
risks
HRs,
39.2
13;
CIs,
2.44-65.7
2.74-61.4;
0.011
0.001,
outcomes.
Hemodialysis
above
poorer
prognoses
regarding
